Keyphrases
Cost-effectiveness
100%
United States
100%
Prostate Cancer
100%
Prostate-specific Antigen Testing
100%
European Studies
100%
Prostate Cancer Risk
40%
Prostate-specific Antigen
40%
Treatment Costs
40%
European Randomized Study of Screening for Prostate Cancer
40%
Life-sustaining Treatment
20%
Overall Mortality
20%
Surveillance Epidemiology
20%
Population-based
20%
Health Care Costs
20%
Medicare Data
20%
Patients with Prostate Cancer
20%
Lifesaving
20%
Screening Protocol
20%
Lifetime Cost
20%
Employers
20%
Number-needed-to-treat
20%
European Data
20%
Minimal Requirements
20%
Nationwide Sample
20%
Screening Cost
20%
Cost-effective Measures
20%
Nursing and Health Professions
Cost Effectiveness Analysis
100%
Prostate Cancer
100%
Prostate Specific Antigen
100%
Antigen
100%
Medicare
12%
Numbers Needed to Treat
12%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Prostate Specific Antigen
100%
Antigen
100%
Number Needed to Treat
12%